Tourmaline closes secondary sale of 11,500,000 Topaz shares for CAD 330.6 million
Bitget2026/10/08 12:56Tourmaline closed a bought-deal secondary offering of 11,500,000 Topaz common shares at CAD 28.75 each. Gross proceeds totaled about CAD 330.6 million; net proceeds to Tourmaline were about CAD 317.4 million. Topaz received no proceeds from the sale. Tourmaline’s Topaz stake fell to 8,431,097 shares, or about 5.4% of shares outstanding, from about 12.9%. Sale framed as part of a long-term plan to reduce its Topaz position while maintaining an investment stake. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tourmaline Oil Corp. published the original content used to generate this news brief via CNW (Ref. ID: 202610080855CANADANWCANADAPR_C6869) on October 08, 2026, and is solely responsible for the information contained therein.
- Tourmaline closed a bought-deal secondary offering of 11,500,000 Topaz common shares at CAD 28.75 each.
- Gross proceeds totaled about CAD 330.6 million; net proceeds to Tourmaline were about CAD 317.4 million.
- Topaz received no proceeds from the sale.
- Tourmaline’s Topaz stake fell to 8,431,097 shares, or about 5.4% of shares outstanding, from about 12.9%.
- Sale framed as part of a long-term plan to reduce its Topaz position while maintaining an investment stake.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
